Ebola virus monoclonal antibodies

Ebola virus causes severe haemorrhagic fever with a high fatality rate. Human-to-human transmission is through contact with body fluids, and recent well-documented outbreaks occurred during 2013–2015 in West Africa. The natural reservoir of this RNA virus is thought to be bats, and several strains of the virus have emerged, including the Zaire, Sudan and Bundi variants.

ViroStat has now introduced new sets of monoclonal antibodies to two of the significant antigens of this virus; nucleoprotein (NP) and VP40. These antibodies function in enzyme-linked immunosorbent assay (ELISA) and Western blot with both the Zaire and Sudan antigen sequences. As such, they offer powerful tools for the development of rapid immunoassays to aid in the detection of this virus.

ViroStat is a primary manufacturer of infectious disease antigens and antibodies, supplying researchers and manufacturers since 1985. Specialties include high-affinity antibodies to influenza A and B, respiratory syncytial virus (RSV) and group A Streptococcus for use in rapid lateral-flow devices as well as antibodies to foodborne pathogens and toxins.

Data sheets on the new Ebola antibodies can be downloaded from the company’s website.




Other news

Upcoming Events

Pathology Horizons 2018 Conference

Lough Erne Resort, Co. Fermanagh, Northern Ireland
September 13-15

Microbe 2018

Hilton Hotel, Sheffield
21-23 September 2018

World Congress of the International Federation of Biomedical Laboratory Science (IFBLS)

Palazza dei Congressi of Firenze
22-26 September 2018

Infection Prevention 2018

Scottish Events Campus, Glasgow
30 September - 2 October 2018

Going Overboard with Microbiology - Women and Children First

Merseyside Maritime Museum, Albert Dock, Liverpool
19 October 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2018

Biomarker testing in suspected pre-eclampsia

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.